Stockreport

Omeros: Key Milestone Ahead, Risk-Averse Investors Should Avoid [Seeking Alpha]

Omeros Corporation  (OMER) 
Last omeros corporation earnings: 3/2 04:03 pm Check Earnings Report
US:NASDAQ Investor Relations: investor.omeros.com
PDF The deal extends OMER's cash runway through 2027, allowing focus on narsoplimab, which awaits a key FDA decision for HSCT-TMA in December 2025. Zaltenibart's out-lice [Read more]